Alphanox to Acquire Additional Shares of U.S. Subsidiary for 5.6 Billion KRW

Alphanox announced on the 19th that it will acquire an additional 4 million shares of its U.S. implant sales subsidiary (Solco Biomedical) for approximately 5.6 billion KRW.

After the acquisition, Alphanox's ownership stake will become 100%. The scheduled date of share acquisition is the 23rd.

The company stated that the purpose of this acquisition is to strengthen business competitiveness in the U.S. market and to improve its financial structure.

This content was produced with the assistance of AI translation services.